drugset / Trial / NCT04995653
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
Phase 1
Completed
60 enrolled
Seres Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
An Open-Label and Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
Timeline
- Start
- 2021-11-24
- Primary completion
- 2024-07-23
- Completion
- 2024-07-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SER-155 | Other / unclassified | — | — |
| Background | Vancomycin | Other / unclassified | — | Oral |